28.06.2010 • NewsBig PharmaMerck & Co.Pfizer

Big Pharma Stocks Could Rally in the Next Year

Wall Street appears to be overly pessimistic about large pharmaceutical companies, and some of the stocks could rally 30% over the next year, according to a cover story in the June 28th edition of Barron's. Some of the best value lies in Merck & Co, Pfizer, Sanofi-Aventis, Novartis and Roche, according to the article in the weekly financial publication. Bristol-Myers Squibb, Eli Lilly and Astrazeneca do not look as attractive as some of their peers, the Barron's article said.

(6/28/2010)

Interview

Stability in Motion
Strategic Response to a Shifting Pharma Landscape

Stability in Motion

Stefan Oelrich, Member of the Board of Management and President Pharmaceuticals, Bayer, discusses navigating external volatility, reshaping its internal structures, and investing in future-ready capabilities to ensure sustainable growth.

Free Expert Insights

Dual‑Targeting Breakthroughs
Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.

most read